SLNO · As filed with the SEC
Soleno Therapeutics cash flow statement, by quarter
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Cash Flows (unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025† 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net income (loss) | 31,378,000 | — | — | — |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||
| Depreciation and amortization | 514,000 | — | — | — |
| Accretion of premium/discount on marketable securities | (221,000) | — | — | — |
| Non-cash lease expense | 149,000 | — | — | — |
| Amortization of debt issuance costs | 8,000 | — | — | — |
| Stock-based compensation expense | 16,056,000 | — | — | — |
| Change in fair value of contingent consideration | 484,000 | — | — | — |
| Other non-cash reconciling items | (28,000) | — | — | — |
| Change in operating assets and liabilities: | ||||
| Accounts receivable | (18,931,000) | — | — | — |
| Inventory | (1,831,000) | — | — | — |
| Prepaid expenses, other current assets and other assets | 780,000 | — | — | — |
| Accounts payable | (2,970,000) | — | — | — |
| Accrued compensation | (3,954,000) | — | — | — |
| Accrued clinical trial site costs | — | — | — | 39,000† |
| Operating lease liabilities | — | — | (115,000)† | (34,000)† |
| Operating lease liabilities | (133,000) | — | — | — |
| Essentialis acquisition milestone payments | (2,954,000) | — | — | — |
| Other liabilities | 7,633,000 | — | — | — |
| Net cash provided by (used in) operating activities | 25,980,000 | — | — | — |
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | (40,000) | — | — | — |
| Purchases of marketable securities | (101,268,000) | — | — | — |
| Maturities of marketable securities | 139,291,000 | — | — | — |
| Net cash provided by investing activities | 37,983,000 | — | — | — |
| Cash flows from financing activities: | ||||
| Payment for repurchase of common stock | (4,000) | — | — | — |
| Payment of debt issuance costs | 0 | — | — | — |
| Proceeds from exercise of common stock warrants | 0 | — | — | — |
| Proceeds from exercise of stock options | 52,000 | — | — | — |
| Tax withholding payments for net share-settled equity awards | (1,000) | — | — | — |
| Essentialis acquisition milestone payments | (1,090,000) | — | — | — |
| Net cash provided by (used in) financing activities | (1,043,000) | — | — | — |
| Net increase (decrease) in cash and cash equivalents | 62,920,000 | — | — | — |
| Cash and cash equivalents, beginning of period | 70,106,000 | 246,662,000 | 76,497,000 | 81,331,000 |
| Cash and cash equivalents, end of period | 133,026,000 | 70,106,000 | 246,662,000 | 76,497,000 |
| Supplemental disclosure of non-cash operating and financing information | ||||
| Cash paid for interest | 1,155,000 | — | — | — |
| Operating lease right-of-use assets obtained in exchange for operating lease obligations | 1,849,000 | — | — | — |
| Purchases of property and equipment included in accounts payable | 4,000 | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.